Lung and breast cancer remain among the leading causes of cancer-related death worldwide. As research, testing and treatment strategies continue to evolve, clinicians must keep abreast of the latest data on molecular mechanisms, emerging therapies, current standards of care, and new strategies for treatment. Whether you are looking for education on the value and interpretation of real-world evidence for clinical decision making in breast cancer care or the efficacy and safety of antibody drug conjugates as therapeutic agents in NSCLC, you’ll find educational activities and resources here to help improve your knowledge and gain insight.

Our activities offer many credit types, including CME, AAFP Prescribed Credit, CNE, CPE, ABIM MOC, and ABP MOC. Each activity has been designed to meet the requirements for CME for MIPS. See each activity’s information page for the exact credit type and amount of credit offered.

The Role of Antibody Drug Conjugates in Advanced Non-Small Cell Lung Cancer: Guidance for Today and the Path Forward

Participate Now!

The discovery of molecular alterations that drive tumor initiation and progression has revolutionized the treatment strategy for non-small cell lung cancer (NSCLC) by matching targeted therapies to a specific mutation, leading to significantly improved therapeutic efficacy. However, despite the initial effectiveness of targeted therapy for NSCLC, most patients ultimately develop acquired resistance with subsequent disease progression, making it imperative for clinicians to receive up-to-date education on evaluating new therapeutic options to improve outcomes and better tailor treatment strategies.

In this CME Outfitters OnDemand, integrations of animated 3-D models will provide visual representation of the mechanisms and characteristics of antibody drug conjugates (ADCs) in NSCLC to complement expert faculty insights and evidence supporting testing strategies to identify predictive biomarkers, emerging treatment options for advanced or metastatic NSCLC, and best practices for managing patients with lung cancer in the face of COVID-19 and beyond.

Targeted Therapy for HER2 and HER3-Positive Breast Cancer: Navigating the Evolving Treatment Landscape

Participate NowBreast cancer (BC) is a heterogeneous disease with human epidermal growth factor receptor 2 (HER2) overexpression and/or amplification observed in 20%-30% of cases. HER2-positive (+) BC correlates with poor clinical outcomes unless appropriately treated with targeted therapy. Despite significant therapeutic advances, many patients experience disease progression with resistance to targeted agents developing over the course of treatment. This CME Outfitters OnDemand webcast will provide up-to-date education on this rapidly evolving field, in order to better tailor treatment strategies, leading to improved patient outcomes. Additionally, faculty will discuss COVID-19 and its impact on patients with BC.

Real-World Evidence: Cyclin-Dependent Kinase 4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer

Participate NowParticipate in this free CME Snack to hear Dr. Martine Piccart discuss randomized, controlled trials, real-world data, and real-world evidence, focusing on the current real-world evidence in the field of cylcin-dependent kinase (CDK) 4/6 inhibitors in metastatic breast cancer. Earn CME/CE credit in just 20 minutes!

Case Challenge: Incorporate Real-World Evidence in the Management of Hormone Receptor-Positive Metastatic Breast Cancer

Participate NowIn this CME Outfitters BriefCase webcast, expert faculty discuss the challenges and nuances of a case scenario as well as practical strategies for incorporating RWE into daily clinical practice in MBC.

Breast Cancer

American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP): Guideline on estrogen and progesterone receptor testing in breast cancer

ASCO/CAP: Clinical practice guideline focused update on human epidermal growth factor receptor 2 testing in breast cancer, update

ASCO: Clinical practice guideline update on recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases

ASCO: Clinical practice guideline update on systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer

ASCO: Guideline on management of male breast cancer

ASCO: Endorsement of the Cancer Care Ontario guideline –Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer, update (2019)

Lung Cancer

ASCO and Ontario Health (Cancer Care Ontario [CCO]): Joint guideline update on therapy for stage IV non-small-cell lung cancer without driver alterations

National Cancer Institute (NCI): Non-small-cell lung cancer–Health professional version

ASCO: Clinical practice guideline on systemic therapy for stage IV non-small-cell lung cancer, update

American Thoracic Society (ATS): Official policy statement for evaluating molecular biomarkers for the early detection of lung cancer

European Society for Medical Oncology (ESMO): Metastatic non-small-cell lung cancer –Clinical practice guidelines for diagnosis, treatment, and follow-up